Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: ALLO-647 added to fludarabine/cyclophosphamide lymphodepletion before ALLO-501A in relapsed/refractory large B-cell lymphoma
2023-503830-27-00Phase 2Completed
- Sponsor
- Allogene Therapeutics
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of cemacabtagene ansegedleucel and allo-647 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Allogene Therapeutics. Primary endpoint: Progression-free survival. Started Aug 2023; status: completed.
02
Drugs
cemacabtagene ansegedleucelallo-647
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-503830-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503830-27-00.